Biocon to fully acquire Biocon Biologics; shares to react Monday.

• Biocon plans to fully merge Biocon Biologics (BBL) as a wholly-owned subsidiary.
• Biocon will acquire minority stakes in BBL from Mylan, Serum, Tata Capital, and Activ Pine via a share swap and cash transfer.
• Biocon shares are expected to react on Monday, December 08, following the merger announcement.
• The company aims to raise up to Rs 4,500 crore through QIP, rights issue, or other methods, mainly to pay Mylan.
• Biocon will issue Rs 1,800 crore in commercial papers for interim cash payment to Mylan until fundraising is complete.

Why It Matters: Biocon's full Biocon Biologics merger and fundraising will reshape its financial future.